Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death

Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~70% for patients with localized disease. Those with disseminated disease have an ~20% 5-year survival. An improved understanding...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 35; no. 40; pp. 5282 - 5294
Main Authors Bhattacharya, S, Chalk, A M, Ng, A J M, Martin, T J, Zannettino, A C, Purton, L E, Lu, J, Baker, E K, Walkley, C R
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 06.10.2016
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~70% for patients with localized disease. Those with disseminated disease have an ~20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were profiled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identified miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To define how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identified that miR-155-5p overexpression suppressed its target Ripk1 (receptor (TNFRSF)-interacting serine–threonine kinase 1) expression, and miR-155-5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS.
AbstractList Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~70% for patients with localized disease. Those with disseminated disease have an ~20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were profiled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identified miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To define how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identified that miR-155-5p overexpression suppressed its target Ripk1 (receptor (TNFRSF)-interacting serine-threonine kinase 1) expression, and miR-155-5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS. Oncogene (2016) 35, 5282-5294; doi: 10.1038/onc.2016.68; published online 4 April 2016
Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~70% for patients with localized disease. Those with disseminated disease have an ~20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were profiled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identified miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To define how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identified that miR-155-5p overexpression suppressed its target Ripk1 (receptor (TNFRSF)-interacting serine-threonine kinase 1) expression, and miR-155-5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS.
Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~ 70% for patients with localized disease. Those with disseminated disease have an ~ 20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were proled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identied miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To dene how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identied that miR-155-5p overexpression suppressed its target Ripk1 (receptor (TNFRSF)-interacting serinethreonine kinase 1) expression, and miR-155-5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS.
Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~70% for patients with localized disease. Those with disseminated disease have an ~20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were profiled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identified miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To define how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identified that miR-155-5p overexpression suppressed its target Ripk1 (receptor (TNFRSF)-interacting serine–threonine kinase 1) expression, and miR-155-5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS.
Audience Academic
Author Martin, T J
Chalk, A M
Zannettino, A C
Baker, E K
Ng, A J M
Purton, L E
Lu, J
Bhattacharya, S
Walkley, C R
Author_xml – sequence: 1
  givenname: S
  surname: Bhattacharya
  fullname: Bhattacharya, S
  organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne
– sequence: 2
  givenname: A M
  surname: Chalk
  fullname: Chalk, A M
  organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne
– sequence: 3
  givenname: A J M
  surname: Ng
  fullname: Ng, A J M
  organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne
– sequence: 4
  givenname: T J
  surname: Martin
  fullname: Martin, T J
  organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne
– sequence: 5
  givenname: A C
  surname: Zannettino
  fullname: Zannettino, A C
  organization: Myeloma Research Laboratory, School of Medicine, Faculty of Health Sciences, University of Adelaide, Cancer Theme, South Australian Health and Medical Research Institute
– sequence: 6
  givenname: L E
  surname: Purton
  fullname: Purton, L E
  organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne, ACRF Rational Drug Discovery Centre, St Vincent’s Institute of Medical Research
– sequence: 7
  givenname: J
  surname: Lu
  fullname: Lu, J
  organization: Department of Genetics and Yale Stem Cell Center, Yale University
– sequence: 8
  givenname: E K
  surname: Baker
  fullname: Baker, E K
  organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne
– sequence: 9
  givenname: C R
  surname: Walkley
  fullname: Walkley, C R
  email: cwalkley@svi.edu.au
  organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne, ACRF Rational Drug Discovery Centre, St Vincent’s Institute of Medical Research
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27041566$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1rHSEUxaWkNC9pV90XoZtCO6_q-LkMIW0DgULJXnx6TSa80anOLPLf1-El6QehuFCuv3s83nOCjlJOgNBbSraU9PpzTn7LCJVbqV-gDeVKdkIYfoQ2xAjSGdazY3RS6x0hRBnCXqFjpginQsoNgsvkC7gKAY_Dj44K0YkJuxRwgbD4xzLXrusn7HOay7BbZsBzxvMt4LpMU4Fah5xwjjjXGXJ1xefRYQ_7PQ7g5tvX6GV0-wpvHvZTdP3l4vr8W3f1_evl-dlV54UWcxej4wJc1CIGSqM2AXpipITgPQ0muJ6LnYwBeC95s0QV79ku-ECNWs-n6MNBdir55wJ1tuNQVxcuQV6qpbpXTVAx0tD3_6B3eSmpmbNMttkYqon8H0U1k6xXirPf1I3bgx1SzHNxfn3annHZxkyoWKntM1RbAcahDRbi0Op_NXw8NPiSay0Q7VSG0ZV7S4ldk7ctebsmb6Vu9LsHq8tuhPDEPkbdgE8HoLardAPlj788o_cLaZW1ww
CODEN ONCNES
CitedBy_id crossref_primary_10_1080_14728222_2023_2263908
crossref_primary_10_2147_CMAR_S302777
crossref_primary_10_1016_j_jconrel_2019_02_007
crossref_primary_10_1111_odi_14655
crossref_primary_10_3892_ijmm_2018_3458
crossref_primary_10_1007_s10555_017_9724_7
crossref_primary_10_1002_jcb_26601
crossref_primary_10_1177_1010428317711539
crossref_primary_10_1038_s41420_022_01261_5
crossref_primary_10_1097_CORR_0000000000000867
crossref_primary_10_1007_s11626_022_00718_2
crossref_primary_10_1042_BST20160131
crossref_primary_10_3390_cancers12082185
crossref_primary_10_1186_s13046_017_0602_5
crossref_primary_10_1016_j_biopha_2020_109880
crossref_primary_10_1038_s41419_018_0813_5
crossref_primary_10_1111_1759_7714_14834
crossref_primary_10_1155_2022_3391878
crossref_primary_10_1016_j_jbo_2018_02_004
crossref_primary_10_1016_j_ejphar_2019_03_034
crossref_primary_10_1007_s10637_018_0624_7
crossref_primary_10_3389_fonc_2021_731598
crossref_primary_10_1016_j_gene_2018_01_049
crossref_primary_10_1016_j_tjog_2022_09_009
crossref_primary_10_1007_s12094_019_02104_z
crossref_primary_10_1038_s41420_021_00596_9
crossref_primary_10_1111_jcmm_14045
crossref_primary_10_1042_BSR20160542
crossref_primary_10_1016_j_fct_2020_111258
crossref_primary_10_1016_j_taap_2019_114616
crossref_primary_10_1111_cas_13177
crossref_primary_10_1177_10732748221076683
crossref_primary_10_1186_s40246_024_00602_y
crossref_primary_10_1007_s10495_022_01760_x
crossref_primary_10_1016_j_ejpb_2018_04_018
crossref_primary_10_3390_cancers14061546
crossref_primary_10_18632_aging_202706
crossref_primary_10_3727_096504017X14850134190255
crossref_primary_10_1096_fj_201801711R
crossref_primary_10_3390_ijms24119392
crossref_primary_10_1016_j_envint_2021_106782
crossref_primary_10_1080_17501911_2024_2354653
crossref_primary_10_3892_ol_2018_8932
crossref_primary_10_1186_s10020_022_00591_5
crossref_primary_10_3892_etm_2018_6845
crossref_primary_10_3892_mmr_2023_13058
crossref_primary_10_1002_kjm2_12442
crossref_primary_10_1016_j_intimp_2023_110603
crossref_primary_10_1016_j_gene_2017_09_027
crossref_primary_10_1016_j_biopha_2019_109627
Cites_doi 10.1038/82732
10.1038/nature13905
10.1158/1078-0432.CCR-11-1714
10.3892/ol.2012.866
10.1002/ijc.2910420408
10.1038/nrm3683
10.1186/gm406
10.1007/s11010-013-1786-4
10.1016/j.molcel.2015.07.032
10.1073/pnas.0804438105
10.1038/onc.2012.305
10.1111/j.1349-7006.2010.01697.x
10.3892/etm.2014.1942
10.1073/pnas.1201516109
10.1373/clinchem.2010.144709
10.1002/ijc.25715
10.1016/j.jbi.2011.05.002
10.1038/cdd.2012.90
10.1002/cncr.24121
10.1371/journal.pone.0127386
10.3892/ijo.2012.1724
10.1136/mp.55.6.389
10.4049/jimmunol.179.8.5082
10.1016/S0092-8674(04)00045-5
10.1006/dbio.1999.9523
10.1128/MCB.17.3.1490
10.7150/ijms.5528
10.1016/j.devcel.2008.03.012
10.1038/sj.cdd.4402085
10.1007/s11010-013-1682-y
10.1200/JCO.2002.20.3.776
10.1073/pnas.0909311106
10.1007/s11010-013-1677-8
10.1016/j.bone.2013.02.016
10.1089/dna.2006.0505
10.1186/1750-1172-8-7
10.1080/07357900802491477
10.1002/pbc.21078
10.1101/gad.1974211
10.1007/s12032-011-0134-3
10.1016/j.cell.2008.03.036
10.1016/S8756-3282(02)00858-X
10.1158/1078-0432.CCR-07-5090
10.1056/NEJMoa1209026
10.1073/pnas.93.20.10923
10.1073/pnas.0707900105
10.1002/jcb.10614
10.1016/0092-8674(95)90072-1
10.1038/bjc.2013.549
10.1158/0008-5472.CAN-11-2663
10.1007/s13277-014-2565-x
10.1101/gad.1656808
10.1371/journal.pone.0053906
ContentType Journal Article
Copyright Macmillan Publishers Limited 2016
COPYRIGHT 2016 Nature Publishing Group
Copyright Nature Publishing Group Oct 6, 2016
Macmillan Publishers Limited 2016.
Copyright_xml – notice: Macmillan Publishers Limited 2016
– notice: COPYRIGHT 2016 Nature Publishing Group
– notice: Copyright Nature Publishing Group Oct 6, 2016
– notice: Macmillan Publishers Limited 2016.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7TM
7TO
7U9
7X7
7XB
88A
88E
8AO
8C1
8FD
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9.
LK8
M0S
M1P
M2O
M7P
MBDVC
P64
PQEST
PQQKQ
PQUKI
PRINS
Q9U
RC3
DOI 10.1038/onc.2016.68
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Research Library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
Genetics Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
Technology Research Database
ProQuest Central Essentials
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest Central (Alumni)
DatabaseTitleList

AIDS and Cancer Research Abstracts
Research Library Prep
Research Library Prep
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
EISSN 1476-5594
EndPage 5294
ExternalDocumentID 4205851551
A465660152
10_1038_onc_2016_68
27041566
Genre Research Support, Non-U.S. Gov't
Journal Article
Feature
GroupedDBID ---
-Q-
0R~
123
29N
2WC
36B
39C
3V.
4.4
406
53G
5RE
70F
7X7
88A
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8R4
8R5
AACDK
AANZL
AASML
AATNV
AAWBL
AAZLF
ABAKF
ABJNI
ABLJU
ABUWG
ABZZP
ACAOD
ACGFO
ACGFS
ACKTT
ACMJI
ACPRK
ACRQY
ACZOJ
ADBBV
ADFRT
ADHDB
AEJRE
AEMSY
AENEX
AEVLU
AEXYK
AFBBN
AFKRA
AFSHS
AGEZK
AGHAI
AGQEE
AHMBA
AHSBF
AIGIU
AILAN
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CCPQU
CS3
DIK
DNIVK
DPUIP
DU5
DWQXO
E3Z
EAP
EBLON
EBS
EE.
EIOEI
EJD
ESX
F5P
FDQFY
FEDTE
FERAY
FIGPU
FIZPM
FSGXE
FYUFA
GNUQQ
GUQSH
HCIFZ
HMCUK
HVGLF
HZ~
IAO
IHR
INH
INR
ITC
IWAJR
JSO
JZLTJ
KQ8
L7B
LK8
M0L
M1P
M2O
M7P
N9A
NAO
NQJWS
NXXTH
O9-
OK1
OVD
P2P
PQQKQ
PROAC
PSQYO
Q2X
RNT
RNTTT
SNX
SNYQT
SOHCF
SRMVM
SWTZT
TAOOD
TBHMF
TDRGL
TEORI
TSG
UKHRP
W2D
WH7
AAYZH
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TM
7TO
7U9
7XB
8FD
8FK
FR3
H94
K9.
MBDVC
P64
PQEST
PQUKI
PRINS
Q9U
RC3
ID FETCH-LOGICAL-c585t-ffa45eaf85fd11f89de30966edcc1d9da345b6fde436448a17432bdcd1971743
IEDL.DBID 8C1
ISSN 0950-9232
IngestDate Thu Oct 24 23:27:49 EDT 2024
Tue Nov 19 05:28:17 EST 2024
Tue Nov 19 04:32:47 EST 2024
Tue Nov 19 21:26:34 EST 2024
Tue Nov 12 22:43:49 EST 2024
Thu Nov 21 22:21:36 EST 2024
Wed Oct 16 00:59:23 EDT 2024
Fri Oct 11 20:46:58 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 40
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c585t-ffa45eaf85fd11f89de30966edcc1d9da345b6fde436448a17432bdcd1971743
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.nature.com/articles/onc201668.pdf
PMID 27041566
PQID 1826237742
PQPubID 36330
PageCount 13
ParticipantIDs proquest_miscellaneous_1837309720
proquest_journals_2641591806
proquest_journals_1826237742
gale_infotracmisc_A465660152
gale_infotracacademiconefile_A465660152
crossref_primary_10_1038_onc_2016_68
pubmed_primary_27041566
springer_journals_10_1038_onc_2016_68
PublicationCentury 2000
PublicationDate 2016-10-06
PublicationDateYYYYMMDD 2016-10-06
PublicationDate_xml – month: 10
  year: 2016
  text: 2016-10-06
  day: 06
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
– name: New York
PublicationTitle Oncogene
PublicationTitleAbbrev Oncogene
PublicationTitleAlternate Oncogene
PublicationYear 2016
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Gougelet, Pissaloux, Besse, Perez, Duc, Dutour (CR14) 2011; 129
Mutsaers, Ng, Baker, Russell, Chalk, Wall (CR20) 2013; 55
Kelly, Haibe-Kains, Janeway, Hill, Howe, Goldsmith (CR32) 2013; 5
Neale, Su, Morton, Phelps, Gorlick, Lock (CR31) 2008; 14
Batanian, Cavalli, Aldosari, Ma, Sotelo-Avila, Ramos (CR40) 2002; 55
Festjens, Vanden Berghe, Cornelis, Vandenabeele (CR43) 2007; 14
Hanoun, Delpu, Suriawinata, Bournet, Bureau, Selves (CR23) 2010; 56
Parkin, Stiller, Draper, Bieber (CR1) 1988; 42
Li, Song, Wang, Luo, Yu (CR33) 2013; 380
Zheng, Liang, Wang, Huang, Cao, Zha (CR34) 2011; 17
Walkley, Qudsi, Sankaran, Perry, Gostissa, Roth (CR19) 2008; 22
Png, Yoshida, Zhang, Shu, Lee, Rimner (CR27) 2011; 25
Grimm, Stanger, Leder (CR42) 1996; 93
Mirabello, Troisi, Savage (CR4) 2009; 115
Lu, Guo, Ebert, Zhang, Peng, Bosco (CR57) 2008; 14
Cheng, Bahal, Babar, Pincus, Barrera, Liu (CR52) 2015; 518
Atkins, Bouralexis, Evdokiou, Hay, Labrinidis, Zannettino (CR55) 2002; 31
Stanger, Leder, Lee, Kim, Seed (CR44) 1995; 81
Hu, Zhang, Cai, Huang, Cai (CR13) 2012; 4
Wang, Du, Wang (CR45) 2008; 133
Janssen, Reesink, Lawitz, Zeuzem, Rodriguez-Torres, Patel (CR54) 2013; 368
Lv, Guo, Li, Jiang (CR37) 2014; 8
Kobayashi, Lu, Cobb, Rodda, McMahon, Schipani (CR7) 2008; 105
Jouan-Lanhouet, Arshad, Piquet-Pellorce, Martin-Chouly, Le Moigne-Muller, Van Herreweghe (CR48) 2012; 19
Babar, Cheng, Booth, Liang, Weidhaas, Saltzman (CR53) 2012; 109
Allan, Ho, Umezawa, Hata, Makishima, Gillespie (CR21) 2003; 90
Bartel (CR5) 2004; 116
Olsen, Ambros (CR6) 1999; 216
Tili, Michaille, Cimino, Costinean, Dumitru, Adair (CR30) 2007; 179
Houghton, Morton, Tucker, Payne, Favours, Cole (CR56) 2007; 49
Neilsen, Noll, Mattiske, Bracken, Gregory, Schulz (CR29) 2013; 32
Dweep, Sticht, Pandey, Gretz (CR28) 2011; 44
Zhang, Harashima, Moritani, Huang, Harada (CR49) 2015; 10
Inose, Ochi, Kimura, Fujita, Xu, Sato (CR9) 2009; 106
Bielack, Kempf-Bielack, Delling, Exner, Flege, Helmke (CR3) 2002; 20
Wu, Zhong, Gao, Zhai, Ding, Wu (CR11) 2013; 10
Tang, Lin, Cai, Tang, Zhou (CR15) 2013; 6
Yen, Chen, Chen, Chen, Chen, Chiou (CR39) 2009; 35
Dondelinger, Jouan-Lanhouet, Divert, Theatre, Bertin, Gough (CR50) 2015; 60
Ma, Zhang, Chai, Chen, Ren, Gong (CR35) 2014; 35
Holler, Zaru, Micheau, Thome, Attinger, Valitutti (CR51) 2000; 1
Zhao, Cai, Yang, Qiu, Liao, Li (CR17) 2013; 8
Dohi, Yasui, Gen, Takada, Endo, Tsuji (CR26) 2013; 42
Tam, Ben-Yehuda, Hayward (CR38) 1997; 17
Geller, Gorlick (CR2) 2010; 8
Li, Hassan, Volinia, van Wijnen, Stein, Croce (CR8) 2008; 105
Kansara, Thomas (CR41) 2007; 26
Ofengeim, Yuan (CR47) 2013; 14
Kim, Ohoka, Okuhira, Sai, Nishimaki-Mogami, Naito (CR46) 2010; 101
Wang, Zhao, Fu (CR22) 2013; 384
Yuan, Ossendorf, Szatkowski, Bronk, Maran, Yaszemski (CR18) 2009; 27
Sun, Song, Wang, Wang, Gao, Chen (CR24) 2014; 7
Zhu, Xia, Zuo, Jin, Zhou, Yao (CR25) 2012; 29
Jones, Salah, Del Mare, Galasso, Gaudio, Nuovo (CR10) 2012; 72
Yang, Gao, Tang, Cai, Lin, Fu (CR16) 2013; 381
Lauvrak, Munthe, Kresse, Stratford, Namlos, Meza-Zepeda (CR36) 2013; 109
Sarver, Thayanithy, Scott, Cleton-Jansen, Hogendoorn, Modiano (CR12) 2013; 8
17911593 - J Immunol. 2007 Oct 15;179(8):5082-9
25409146 - Nature. 2015 Feb 5;518(7537):107-10
18238902 - Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1949-54
24129419 - Nat Rev Mol Cell Biol. 2013 Nov;14(11):727-36
11821461 - J Clin Oncol. 2002 Feb 1;20(3):776-90
26344099 - Mol Cell. 2015 Oct 1;60(1):63-76
12456778 - Mol Pathol. 2002 Dec;55(6):389-93
23486187 - Bone. 2013 Jul;55(1):166-78
23534542 - N Engl J Med. 2013 May 2;368(18):1685-94
23162647 - Oncol Lett. 2012 Nov;4(5):1037-1042
24920927 - Onco Targets Ther. 2014 May 28;7:853-63
23975506 - Mol Cell Biochem. 2013 Dec;384(1-2):105-11
12938165 - J Cell Biochem. 2003 Sep 1;90(1):158-69
11101870 - Nat Immunol. 2000 Dec;1(6):489-95
21994419 - Clin Cancer Res. 2011 Dec 15;17 (24):7574-83
7538908 - Cell. 1995 May 19;81(4):513-23
20949564 - Int J Cancer. 2011 Aug 1;129(3):680-90
22167392 - Med Oncol. 2012 Dec;29(4):2701-9
23670799 - Mol Cell Biochem. 2013 Aug;380(1-2):277-82
18784367 - Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):13906-11
19197972 - Cancer. 2009 Apr 1;115(7):1531-43
22797073 - Oncogene. 2013 Jun 13;32(24):2992-3000
23874105 - Onco Targets Ther. 2013 Jul 08;6:833-8
21605702 - J Biomed Inform. 2011 Oct;44(5):839-47
18539114 - Dev Cell. 2008 Jun;14(6):843-53
10642801 - Dev Biol. 1999 Dec 15;216(2):671-80
14744438 - Cell. 2004 Jan 23;116(2):281-97
17301840 - Cell Death Differ. 2007 Mar;14 (3):400-10
25289062 - Exp Ther Med. 2014 Nov;8(5):1575-1580
21289068 - Genes Dev. 2011 Feb 1;25(3):226-31
3170025 - Int J Cancer. 1988 Oct 15;42(4):511-20
18628472 - Clin Cancer Res. 2008 Jul 15;14(14):4572-83
23569431 - Int J Med Sci. 2013;10(6):676-82
22350417 - Cancer Res. 2012 Apr 1;72(7):1865-77
9032277 - Mol Cell Biol. 1997 Mar;17(3):1490-502
23339462 - Genome Med. 2013 Jan 22;5(1):2
26000607 - PLoS One. 2015 May 22;10 (5):e0127386
23311495 - Orphanet J Rare Dis. 2013 Jan 11;8:7
23229728 - Int J Oncol. 2013 Feb;42(2):411-8
25185654 - Tumour Biol. 2014 Dec;35(12):12467-72
22814620 - Cell Death Differ. 2012 Dec;19(12 ):2003-14
19724913 - Int J Oncol. 2009 Oct;35(4):775-88
18485876 - Cell. 2008 May 16;133(4):693-703
8855284 - Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10923-7
24064976 - Br J Cancer. 2013 Oct 15;109(8):2228-36
18559481 - Genes Dev. 2008 Jun 15;22(12):1662-76
19933329 - Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20794-9
17066459 - Pediatr Blood Cancer. 2007 Dec;49(7):928-40
23801049 - Mol Cell Biochem. 2013 Sep;381(1-2):9-15
22685206 - Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):E1695-704
19212826 - Cancer Invest. 2009 May;27(4):435-42
17263592 - DNA Cell Biol. 2007 Jan;26(1):1-18
21317869 - Clin Adv Hematol Oncol. 2010 Oct;8(10):705-18
23372675 - PLoS One. 2013;8(1):e53906
20431052 - Clin Chem. 2010 Jul;56(7):1107-18
20825417 - Cancer Sci. 2010 Nov;101(11):2425-9
12398939 - Bone. 2002 Oct;31(4):448-56
JR Batanian (BFonc201668_CR40) 2002; 55
J Yang (BFonc201668_CR16) 2013; 381
H Lv (BFonc201668_CR37) 2014; 8
PH Olsen (BFonc201668_CR6) 1999; 216
N Festjens (BFonc201668_CR43) 2007; 14
PJ Houghton (BFonc201668_CR56) 2007; 49
J Sun (BFonc201668_CR24) 2014; 7
SU Lauvrak (BFonc201668_CR36) 2013; 109
BZ Stanger (BFonc201668_CR44) 1995; 81
L Wang (BFonc201668_CR45) 2008; 133
J Lu (BFonc201668_CR57) 2008; 14
Y Wang (BFonc201668_CR22) 2013; 384
B Zheng (BFonc201668_CR34) 2011; 17
L Mirabello (BFonc201668_CR4) 2009; 115
A Gougelet (BFonc201668_CR14) 2011; 129
H Dweep (BFonc201668_CR28) 2011; 44
H Hu (BFonc201668_CR13) 2012; 4
O Dohi (BFonc201668_CR26) 2013; 42
KB Jones (BFonc201668_CR10) 2012; 72
E Tili (BFonc201668_CR30) 2007; 179
AL Sarver (BFonc201668_CR12) 2013; 8
G Neale (BFonc201668_CR31) 2008; 14
H Inose (BFonc201668_CR9) 2009; 106
T Kobayashi (BFonc201668_CR7) 2008; 105
CC Yen (BFonc201668_CR39) 2009; 35
M Kansara (BFonc201668_CR41) 2007; 26
CJ Cheng (BFonc201668_CR52) 2015; 518
EH Allan (BFonc201668_CR21) 2003; 90
J Yuan (BFonc201668_CR18) 2009; 27
D Ofengeim (BFonc201668_CR47) 2013; 14
M Zhang (BFonc201668_CR49) 2015; 10
GJ Atkins (BFonc201668_CR55) 2002; 31
DM Parkin (BFonc201668_CR1) 1988; 42
G Zhao (BFonc201668_CR17) 2013; 8
W Ma (BFonc201668_CR35) 2014; 35
N Holler (BFonc201668_CR51) 2000; 1
S Kim (BFonc201668_CR46) 2010; 101
PM Neilsen (BFonc201668_CR29) 2013; 32
Y Dondelinger (BFonc201668_CR50) 2015; 60
Z Li (BFonc201668_CR8) 2008; 105
X Wu (BFonc201668_CR11) 2013; 10
N Hanoun (BFonc201668_CR23) 2010; 56
CR Walkley (BFonc201668_CR19) 2008; 22
DS Geller (BFonc201668_CR2) 2010; 8
S Grimm (BFonc201668_CR42) 1996; 93
S Jouan-Lanhouet (BFonc201668_CR48) 2012; 19
A Zhu (BFonc201668_CR25) 2012; 29
SS Bielack (BFonc201668_CR3) 2002; 20
HL Janssen (BFonc201668_CR54) 2013; 368
AJ Mutsaers (BFonc201668_CR20) 2013; 55
J Li (BFonc201668_CR33) 2013; 380
KJ Png (BFonc201668_CR27) 2011; 25
IA Babar (BFonc201668_CR53) 2012; 109
W Tam (BFonc201668_CR38) 1997; 17
DP Bartel (BFonc201668_CR5) 2004; 116
AD Kelly (BFonc201668_CR32) 2013; 5
M Tang (BFonc201668_CR15) 2013; 6
References_xml – volume: 7
  start-page: 853
  year: 2014
  end-page: 863
  ident: CR24
  article-title: Clinical significance of promoter region hypermethylation of microRNA-148a in gastrointestinal cancers
  publication-title: Onco Targets Ther
  contributor:
    fullname: Chen
– volume: 1
  start-page: 489
  year: 2000
  end-page: 495
  ident: CR51
  article-title: Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule
  publication-title: Nat Immunol
  doi: 10.1038/82732
  contributor:
    fullname: Valitutti
– volume: 518
  start-page: 107
  year: 2015
  end-page: 110
  ident: CR52
  article-title: MicroRNA silencing for cancer therapy targeted to the tumour microenvironment
  publication-title: Nature
  doi: 10.1038/nature13905
  contributor:
    fullname: Liu
– volume: 17
  start-page: 7574
  year: 2011
  end-page: 7583
  ident: CR34
  article-title: MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-1714
  contributor:
    fullname: Zha
– volume: 4
  start-page: 1037
  year: 2012
  end-page: 1042
  ident: CR13
  article-title: Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts
  publication-title: Oncol Lett
  doi: 10.3892/ol.2012.866
  contributor:
    fullname: Cai
– volume: 42
  start-page: 511
  year: 1988
  end-page: 520
  ident: CR1
  article-title: The international incidence of childhood cancer
  publication-title: Int J Cancer
  doi: 10.1002/ijc.2910420408
  contributor:
    fullname: Bieber
– volume: 8
  start-page: 705
  year: 2010
  end-page: 718
  ident: CR2
  article-title: Osteosarcoma: a review of diagnosis, management, and treatment strategies
  publication-title: Clin Adv Hematol Oncol
  contributor:
    fullname: Gorlick
– volume: 14
  start-page: 727
  year: 2013
  end-page: 736
  ident: CR47
  article-title: Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm3683
  contributor:
    fullname: Yuan
– volume: 5
  start-page: 2
  year: 2013
  ident: CR32
  article-title: MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32
  publication-title: Genome Med
  doi: 10.1186/gm406
  contributor:
    fullname: Goldsmith
– volume: 384
  start-page: 105
  year: 2013
  end-page: 111
  ident: CR22
  article-title: miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-013-1786-4
  contributor:
    fullname: Fu
– volume: 60
  start-page: 63
  year: 2015
  end-page: 76
  ident: CR50
  article-title: NF-kappaB-independent role of IKKalpha/IKKbeta in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during tnf signaling
  publication-title: Mol Cell.
  doi: 10.1016/j.molcel.2015.07.032
  contributor:
    fullname: Gough
– volume: 105
  start-page: 13906
  year: 2008
  end-page: 13911
  ident: CR8
  article-title: A microRNA signature for a BMP2-induced osteoblast lineage commitment program
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0804438105
  contributor:
    fullname: Croce
– volume: 32
  start-page: 2992
  year: 2013
  end-page: 3000
  ident: CR29
  article-title: Mutant p53 drives invasion in breast tumors through up-regulation of miR-155
  publication-title: Oncogene
  doi: 10.1038/onc.2012.305
  contributor:
    fullname: Schulz
– volume: 101
  start-page: 2425
  year: 2010
  end-page: 2429
  ident: CR46
  article-title: Modulation of RIP1 ubiquitylation and distribution by MeBS to sensitize cancer cells to tumor necrosis factor alpha-induced apoptosis
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2010.01697.x
  contributor:
    fullname: Naito
– volume: 8
  start-page: 1575
  year: 2014
  end-page: 1580
  ident: CR37
  article-title: inhibitor reduces the proliferation and migration in osteosarcoma MG-63 cells
  publication-title: Exp Ther Med
  doi: 10.3892/etm.2014.1942
  contributor:
    fullname: Jiang
– volume: 109
  start-page: E1695
  year: 2012
  end-page: E1704
  ident: CR53
  article-title: Nanoparticle-based therapy in an microRNA-155 (miR-155)-dependent mouse model of lymphoma
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1201516109
  contributor:
    fullname: Saltzman
– volume: 56
  start-page: 1107
  year: 2010
  end-page: 1118
  ident: CR23
  article-title: The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2010.144709
  contributor:
    fullname: Selves
– volume: 129
  start-page: 680
  year: 2011
  end-page: 690
  ident: CR14
  article-title: Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response
  publication-title: Int J Cancer
  doi: 10.1002/ijc.25715
  contributor:
    fullname: Dutour
– volume: 44
  start-page: 839
  year: 2011
  end-page: 847
  ident: CR28
  article-title: miRWalk—database: prediction of possible miRNA binding sites by "walking" the genes of three genomes
  publication-title: J Biomed Inform
  doi: 10.1016/j.jbi.2011.05.002
  contributor:
    fullname: Gretz
– volume: 19
  start-page: 2003
  year: 2012
  end-page: 2014
  ident: CR48
  article-title: TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2012.90
  contributor:
    fullname: Van Herreweghe
– volume: 115
  start-page: 1531
  year: 2009
  end-page: 1543
  ident: CR4
  article-title: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program
  publication-title: Cancer
  doi: 10.1002/cncr.24121
  contributor:
    fullname: Savage
– volume: 10
  start-page: e0127386
  year: 2015
  ident: CR49
  article-title: The Roles of ROS and Caspases in TRAIL-Induced Apoptosis and Necroptosis in Human Pancreatic Cancer Cells
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0127386
  contributor:
    fullname: Harada
– volume: 42
  start-page: 411
  year: 2013
  end-page: 418
  ident: CR26
  article-title: Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2012.1724
  contributor:
    fullname: Tsuji
– volume: 55
  start-page: 389
  year: 2002
  end-page: 393
  ident: CR40
  article-title: Evaluation of paediatric osteosarcomas by classic cytogenetic and CGH analyses
  publication-title: Mol Pathol
  doi: 10.1136/mp.55.6.389
  contributor:
    fullname: Ramos
– volume: 179
  start-page: 5082
  year: 2007
  end-page: 5089
  ident: CR30
  article-title: Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock
  publication-title: J Immunol
  doi: 10.4049/jimmunol.179.8.5082
  contributor:
    fullname: Adair
– volume: 116
  start-page: 281
  year: 2004
  end-page: 297
  ident: CR5
  article-title: MicroRNAs: genomics, biogenesis, mechanism, and function
  publication-title: Cell
  doi: 10.1016/S0092-8674(04)00045-5
  contributor:
    fullname: Bartel
– volume: 216
  start-page: 671
  year: 1999
  end-page: 680
  ident: CR6
  article-title: The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation
  publication-title: Dev Biol
  doi: 10.1006/dbio.1999.9523
  contributor:
    fullname: Ambros
– volume: 17
  start-page: 1490
  year: 1997
  end-page: 1502
  ident: CR38
  article-title: bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.17.3.1490
  contributor:
    fullname: Hayward
– volume: 10
  start-page: 676
  year: 2013
  end-page: 682
  ident: CR11
  article-title: MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether a go-go 1 expression
  publication-title: Int J Med Sci
  doi: 10.7150/ijms.5528
  contributor:
    fullname: Wu
– volume: 14
  start-page: 843
  year: 2008
  end-page: 853
  ident: CR57
  article-title: MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors
  publication-title: Dev Cell
  doi: 10.1016/j.devcel.2008.03.012
  contributor:
    fullname: Bosco
– volume: 14
  start-page: 400
  year: 2007
  end-page: 410
  ident: CR43
  article-title: RIP1, a kinase on the crossroads of a cell's decision to live or die
  publication-title: Cell Death Differ
  doi: 10.1038/sj.cdd.4402085
  contributor:
    fullname: Vandenabeele
– volume: 380
  start-page: 277
  year: 2013
  end-page: 282
  ident: CR33
  article-title: MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-013-1682-y
  contributor:
    fullname: Yu
– volume: 20
  start-page: 776
  year: 2002
  end-page: 790
  ident: CR3
  article-title: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2002.20.3.776
  contributor:
    fullname: Helmke
– volume: 106
  start-page: 20794
  year: 2009
  end-page: 20799
  ident: CR9
  article-title: A microRNA regulatory mechanism of osteoblast differentiation
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0909311106
  contributor:
    fullname: Sato
– volume: 381
  start-page: 9
  year: 2013
  end-page: 15
  ident: CR16
  article-title: Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-013-1677-8
  contributor:
    fullname: Fu
– volume: 55
  start-page: 166
  year: 2013
  end-page: 178
  ident: CR20
  article-title: Modeling distinct osteosarcoma subtypes using Cre:lox and lineage-restricted transgenic shRNA
  publication-title: Bone
  doi: 10.1016/j.bone.2013.02.016
  contributor:
    fullname: Wall
– volume: 26
  start-page: 1
  year: 2007
  end-page: 18
  ident: CR41
  article-title: Molecular pathogenesis of osteosarcoma
  publication-title: DNA Cell Biol
  doi: 10.1089/dna.2006.0505
  contributor:
    fullname: Thomas
– volume: 8
  start-page: 7
  year: 2013
  ident: CR12
  article-title: MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma
  publication-title: Orphanet J Rare Dis
  doi: 10.1186/1750-1172-8-7
  contributor:
    fullname: Modiano
– volume: 27
  start-page: 435
  year: 2009
  end-page: 442
  ident: CR18
  article-title: Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases
  publication-title: Cancer Invest
  doi: 10.1080/07357900802491477
  contributor:
    fullname: Yaszemski
– volume: 49
  start-page: 928
  year: 2007
  end-page: 940
  ident: CR56
  article-title: The pediatric preclinical testing program: description of models and early testing results
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.21078
  contributor:
    fullname: Cole
– volume: 25
  start-page: 226
  year: 2011
  end-page: 231
  ident: CR27
  article-title: MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer
  publication-title: Genes Dev
  doi: 10.1101/gad.1974211
  contributor:
    fullname: Rimner
– volume: 29
  start-page: 2701
  year: 2012
  end-page: 2709
  ident: CR25
  article-title: MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer
  publication-title: Med Oncol
  doi: 10.1007/s12032-011-0134-3
  contributor:
    fullname: Yao
– volume: 133
  start-page: 693
  year: 2008
  end-page: 703
  ident: CR45
  article-title: TNF-alpha induces two distinct caspase-8 activation pathways
  publication-title: Cell
  doi: 10.1016/j.cell.2008.03.036
  contributor:
    fullname: Wang
– volume: 31
  start-page: 448
  year: 2002
  end-page: 456
  ident: CR55
  article-title: Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis
  publication-title: Bone
  doi: 10.1016/S8756-3282(02)00858-X
  contributor:
    fullname: Zannettino
– volume: 14
  start-page: 4572
  year: 2008
  end-page: 4583
  ident: CR31
  article-title: Molecular characterization of the pediatric preclinical testing panel
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-5090
  contributor:
    fullname: Lock
– volume: 368
  start-page: 1685
  year: 2013
  end-page: 1694
  ident: CR54
  article-title: Treatment of HCV infection by targeting microRNA
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1209026
  contributor:
    fullname: Patel
– volume: 93
  start-page: 10923
  year: 1996
  end-page: 10927
  ident: CR42
  article-title: RIP and FADD: two "death domain"-containing proteins can induce apoptosis by convergent, but dissociable, pathways
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.93.20.10923
  contributor:
    fullname: Leder
– volume: 105
  start-page: 1949
  year: 2008
  end-page: 1954
  ident: CR7
  article-title: Dicer-dependent pathways regulate chondrocyte proliferation and differentiation
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0707900105
  contributor:
    fullname: Schipani
– volume: 90
  start-page: 158
  year: 2003
  end-page: 169
  ident: CR21
  article-title: Differentiation potential of a mouse bone marrow stromal cell line
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.10614
  contributor:
    fullname: Gillespie
– volume: 81
  start-page: 513
  year: 1995
  end-page: 523
  ident: CR44
  article-title: RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death
  publication-title: Cell
  doi: 10.1016/0092-8674(95)90072-1
  contributor:
    fullname: Seed
– volume: 109
  start-page: 2228
  year: 2013
  end-page: 2236
  ident: CR36
  article-title: Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2013.549
  contributor:
    fullname: Meza-Zepeda
– volume: 6
  start-page: 833
  year: 2013
  end-page: 838
  ident: CR15
  article-title: MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patients suffering osteosarcoma
  publication-title: Onco Targets Ther
  contributor:
    fullname: Zhou
– volume: 35
  start-page: 775
  year: 2009
  end-page: 788
  ident: CR39
  article-title: Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcoma
  publication-title: Int J Oncol
  contributor:
    fullname: Chiou
– volume: 72
  start-page: 1865
  year: 2012
  end-page: 1877
  ident: CR10
  article-title: miRNA signatures associate with pathogenesis and progression of osteosarcoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-2663
  contributor:
    fullname: Nuovo
– volume: 35
  start-page: 12467
  year: 2014
  end-page: 12472
  ident: CR35
  article-title: Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma
  publication-title: Tumour Biol
  doi: 10.1007/s13277-014-2565-x
  contributor:
    fullname: Gong
– volume: 22
  start-page: 1662
  year: 2008
  end-page: 1676
  ident: CR19
  article-title: Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease
  publication-title: Genes Dev
  doi: 10.1101/gad.1656808
  contributor:
    fullname: Roth
– volume: 8
  start-page: e53906
  year: 2013
  ident: CR17
  article-title: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0053906
  contributor:
    fullname: Li
– volume: 81
  start-page: 513
  year: 1995
  ident: BFonc201668_CR44
  publication-title: Cell
  doi: 10.1016/0092-8674(95)90072-1
  contributor:
    fullname: BZ Stanger
– volume: 22
  start-page: 1662
  year: 2008
  ident: BFonc201668_CR19
  publication-title: Genes Dev
  doi: 10.1101/gad.1656808
  contributor:
    fullname: CR Walkley
– volume: 31
  start-page: 448
  year: 2002
  ident: BFonc201668_CR55
  publication-title: Bone
  doi: 10.1016/S8756-3282(02)00858-X
  contributor:
    fullname: GJ Atkins
– volume: 216
  start-page: 671
  year: 1999
  ident: BFonc201668_CR6
  publication-title: Dev Biol
  doi: 10.1006/dbio.1999.9523
  contributor:
    fullname: PH Olsen
– volume: 6
  start-page: 833
  year: 2013
  ident: BFonc201668_CR15
  publication-title: Onco Targets Ther
  contributor:
    fullname: M Tang
– volume: 35
  start-page: 12467
  year: 2014
  ident: BFonc201668_CR35
  publication-title: Tumour Biol
  doi: 10.1007/s13277-014-2565-x
  contributor:
    fullname: W Ma
– volume: 14
  start-page: 400
  year: 2007
  ident: BFonc201668_CR43
  publication-title: Cell Death Differ
  doi: 10.1038/sj.cdd.4402085
  contributor:
    fullname: N Festjens
– volume: 380
  start-page: 277
  year: 2013
  ident: BFonc201668_CR33
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-013-1682-y
  contributor:
    fullname: J Li
– volume: 8
  start-page: 705
  year: 2010
  ident: BFonc201668_CR2
  publication-title: Clin Adv Hematol Oncol
  contributor:
    fullname: DS Geller
– volume: 368
  start-page: 1685
  year: 2013
  ident: BFonc201668_CR54
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1209026
  contributor:
    fullname: HL Janssen
– volume: 5
  start-page: 2
  year: 2013
  ident: BFonc201668_CR32
  publication-title: Genome Med
  doi: 10.1186/gm406
  contributor:
    fullname: AD Kelly
– volume: 25
  start-page: 226
  year: 2011
  ident: BFonc201668_CR27
  publication-title: Genes Dev
  doi: 10.1101/gad.1974211
  contributor:
    fullname: KJ Png
– volume: 109
  start-page: E1695
  year: 2012
  ident: BFonc201668_CR53
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1201516109
  contributor:
    fullname: IA Babar
– volume: 42
  start-page: 411
  year: 2013
  ident: BFonc201668_CR26
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2012.1724
  contributor:
    fullname: O Dohi
– volume: 101
  start-page: 2425
  year: 2010
  ident: BFonc201668_CR46
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2010.01697.x
  contributor:
    fullname: S Kim
– volume: 19
  start-page: 2003
  year: 2012
  ident: BFonc201668_CR48
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2012.90
  contributor:
    fullname: S Jouan-Lanhouet
– volume: 8
  start-page: e53906
  year: 2013
  ident: BFonc201668_CR17
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0053906
  contributor:
    fullname: G Zhao
– volume: 179
  start-page: 5082
  year: 2007
  ident: BFonc201668_CR30
  publication-title: J Immunol
  doi: 10.4049/jimmunol.179.8.5082
  contributor:
    fullname: E Tili
– volume: 115
  start-page: 1531
  year: 2009
  ident: BFonc201668_CR4
  publication-title: Cancer
  doi: 10.1002/cncr.24121
  contributor:
    fullname: L Mirabello
– volume: 10
  start-page: 676
  year: 2013
  ident: BFonc201668_CR11
  publication-title: Int J Med Sci
  doi: 10.7150/ijms.5528
  contributor:
    fullname: X Wu
– volume: 14
  start-page: 4572
  year: 2008
  ident: BFonc201668_CR31
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-5090
  contributor:
    fullname: G Neale
– volume: 49
  start-page: 928
  year: 2007
  ident: BFonc201668_CR56
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.21078
  contributor:
    fullname: PJ Houghton
– volume: 381
  start-page: 9
  year: 2013
  ident: BFonc201668_CR16
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-013-1677-8
  contributor:
    fullname: J Yang
– volume: 116
  start-page: 281
  year: 2004
  ident: BFonc201668_CR5
  publication-title: Cell
  doi: 10.1016/S0092-8674(04)00045-5
  contributor:
    fullname: DP Bartel
– volume: 55
  start-page: 389
  year: 2002
  ident: BFonc201668_CR40
  publication-title: Mol Pathol
  doi: 10.1136/mp.55.6.389
  contributor:
    fullname: JR Batanian
– volume: 1
  start-page: 489
  year: 2000
  ident: BFonc201668_CR51
  publication-title: Nat Immunol
  doi: 10.1038/82732
  contributor:
    fullname: N Holler
– volume: 72
  start-page: 1865
  year: 2012
  ident: BFonc201668_CR10
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-2663
  contributor:
    fullname: KB Jones
– volume: 10
  start-page: e0127386
  year: 2015
  ident: BFonc201668_CR49
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0127386
  contributor:
    fullname: M Zhang
– volume: 27
  start-page: 435
  year: 2009
  ident: BFonc201668_CR18
  publication-title: Cancer Invest
  doi: 10.1080/07357900802491477
  contributor:
    fullname: J Yuan
– volume: 4
  start-page: 1037
  year: 2012
  ident: BFonc201668_CR13
  publication-title: Oncol Lett
  doi: 10.3892/ol.2012.866
  contributor:
    fullname: H Hu
– volume: 93
  start-page: 10923
  year: 1996
  ident: BFonc201668_CR42
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.93.20.10923
  contributor:
    fullname: S Grimm
– volume: 55
  start-page: 166
  year: 2013
  ident: BFonc201668_CR20
  publication-title: Bone
  doi: 10.1016/j.bone.2013.02.016
  contributor:
    fullname: AJ Mutsaers
– volume: 26
  start-page: 1
  year: 2007
  ident: BFonc201668_CR41
  publication-title: DNA Cell Biol
  doi: 10.1089/dna.2006.0505
  contributor:
    fullname: M Kansara
– volume: 105
  start-page: 1949
  year: 2008
  ident: BFonc201668_CR7
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0707900105
  contributor:
    fullname: T Kobayashi
– volume: 109
  start-page: 2228
  year: 2013
  ident: BFonc201668_CR36
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2013.549
  contributor:
    fullname: SU Lauvrak
– volume: 20
  start-page: 776
  year: 2002
  ident: BFonc201668_CR3
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2002.20.3.776
  contributor:
    fullname: SS Bielack
– volume: 17
  start-page: 7574
  year: 2011
  ident: BFonc201668_CR34
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-1714
  contributor:
    fullname: B Zheng
– volume: 106
  start-page: 20794
  year: 2009
  ident: BFonc201668_CR9
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0909311106
  contributor:
    fullname: H Inose
– volume: 32
  start-page: 2992
  year: 2013
  ident: BFonc201668_CR29
  publication-title: Oncogene
  doi: 10.1038/onc.2012.305
  contributor:
    fullname: PM Neilsen
– volume: 384
  start-page: 105
  year: 2013
  ident: BFonc201668_CR22
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-013-1786-4
  contributor:
    fullname: Y Wang
– volume: 29
  start-page: 2701
  year: 2012
  ident: BFonc201668_CR25
  publication-title: Med Oncol
  doi: 10.1007/s12032-011-0134-3
  contributor:
    fullname: A Zhu
– volume: 42
  start-page: 511
  year: 1988
  ident: BFonc201668_CR1
  publication-title: Int J Cancer
  doi: 10.1002/ijc.2910420408
  contributor:
    fullname: DM Parkin
– volume: 8
  start-page: 1575
  year: 2014
  ident: BFonc201668_CR37
  publication-title: Exp Ther Med
  doi: 10.3892/etm.2014.1942
  contributor:
    fullname: H Lv
– volume: 518
  start-page: 107
  year: 2015
  ident: BFonc201668_CR52
  publication-title: Nature
  doi: 10.1038/nature13905
  contributor:
    fullname: CJ Cheng
– volume: 133
  start-page: 693
  year: 2008
  ident: BFonc201668_CR45
  publication-title: Cell
  doi: 10.1016/j.cell.2008.03.036
  contributor:
    fullname: L Wang
– volume: 105
  start-page: 13906
  year: 2008
  ident: BFonc201668_CR8
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0804438105
  contributor:
    fullname: Z Li
– volume: 14
  start-page: 843
  year: 2008
  ident: BFonc201668_CR57
  publication-title: Dev Cell
  doi: 10.1016/j.devcel.2008.03.012
  contributor:
    fullname: J Lu
– volume: 7
  start-page: 853
  year: 2014
  ident: BFonc201668_CR24
  publication-title: Onco Targets Ther
  contributor:
    fullname: J Sun
– volume: 8
  start-page: 7
  year: 2013
  ident: BFonc201668_CR12
  publication-title: Orphanet J Rare Dis
  doi: 10.1186/1750-1172-8-7
  contributor:
    fullname: AL Sarver
– volume: 56
  start-page: 1107
  year: 2010
  ident: BFonc201668_CR23
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2010.144709
  contributor:
    fullname: N Hanoun
– volume: 44
  start-page: 839
  year: 2011
  ident: BFonc201668_CR28
  publication-title: J Biomed Inform
  doi: 10.1016/j.jbi.2011.05.002
  contributor:
    fullname: H Dweep
– volume: 60
  start-page: 63
  year: 2015
  ident: BFonc201668_CR50
  publication-title: Mol Cell.
  doi: 10.1016/j.molcel.2015.07.032
  contributor:
    fullname: Y Dondelinger
– volume: 17
  start-page: 1490
  year: 1997
  ident: BFonc201668_CR38
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.17.3.1490
  contributor:
    fullname: W Tam
– volume: 90
  start-page: 158
  year: 2003
  ident: BFonc201668_CR21
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.10614
  contributor:
    fullname: EH Allan
– volume: 35
  start-page: 775
  year: 2009
  ident: BFonc201668_CR39
  publication-title: Int J Oncol
  contributor:
    fullname: CC Yen
– volume: 129
  start-page: 680
  year: 2011
  ident: BFonc201668_CR14
  publication-title: Int J Cancer
  doi: 10.1002/ijc.25715
  contributor:
    fullname: A Gougelet
– volume: 14
  start-page: 727
  year: 2013
  ident: BFonc201668_CR47
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm3683
  contributor:
    fullname: D Ofengeim
SSID ssj0007902
Score 2.5038416
Snippet Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have...
SourceID proquest
gale
crossref
pubmed
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 5282
SubjectTerms 13/2
13/31
13/89
38/39
38/90
631/67/1798
64/60
82/80
Analysis
Animal models
Animals
Apoptosis
Apoptosis - genetics
Biochemistry
Bone cancer
Cell Biology
Cell death
Cell Differentiation - genetics
Cell fate
Cell Line, Tumor
Cell proliferation
Cell Proliferation - genetics
Computer applications
Disease Models, Animal
Gene Expression Regulation, Neoplastic
Genetic engineering
Genetically modified organisms
Human Genetics
Humans
Internal Medicine
Medicine
Medicine & Public Health
Metastases
Mice
MicroRNA
MicroRNAs
MicroRNAs - biosynthesis
MicroRNAs - genetics
miRNA
Necroptosis
Oncology
original-article
Osteoblasts
Osteosarcoma
Osteosarcoma - genetics
Osteosarcoma - pathology
Protein-serine/threonine kinase
Receptor-Interacting Protein Serine-Threonine Kinases - genetics
Sarcoma
siRNA
Tumor cells
Wildlife conservation
Young adults
Title Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death
URI https://link.springer.com/article/10.1038/onc.2016.68
https://www.ncbi.nlm.nih.gov/pubmed/27041566
https://www.proquest.com/docview/1826237742
https://www.proquest.com/docview/2641591806
https://search.proquest.com/docview/1837309720
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7RVlAuCJZXoKyMVMTJNHFsxzmhsmpVIbVCVZH2Fjl-SByahN3sof8eT-K024K4RbHlxB575hvPC-BQMlNz4RhlzNeUB_hGa5dxyqXJ61pKJQsMTj6_kGc_-felWMYLt3V0q5x44sCobWvwjvwoCO4geTOVyq_db4pVo9C6Gkto7MBehoIOI8UXdy4exehzGFBESgOQYTE-L83VUdtg_sJMfsEcq1sS6SFf3hJMDyylgwA6fQ7PInIkxyOpX8Aj18zg8VhL8mYG-4updNsMnpxHi_lLcIEBoN-5s-T61yUNcp2KjujGkhUmbZ1ec6Vp3pHBcR0rYDnStyRgQ7LedNFVtiGtJxgS0q7D4WivNcFLf2IRQ76Cq9OTq8UZjaUVqAn6QU-914FC2ivhbZZ5VVqXB2VGOmtMZkurcy5q6a3jOSpwGvUWVltjs7LA59ew27SNewtE-UxJLXShreFcl0qkOJ6ohVXMC5PA4bS6VTcm0KgGw3euqkCEColQSZXAZ1z5Co9Vv9JGx-iA8BFMUFUdY163oDwKlsDBvZ5hac395ol2VTyO6wqVKJYHpPvv5ru9lcDH22YcGD3QGtducIg8MMOyYGkCb8YtcTsfVqSDHpzAp2mPbH3778m--_9PvIen2HFwGZQHsNuvNu5DgD59PYedYlnMh10-h71vJxc_Lv8AmXsAhQ
link.rule.ids 314,780,784,12056,12223,21388,27924,27925,31719,31720,33266,33267,33744,33745,43310,43579,43805,73745,74014,74302
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVlAuCJZXoICRiji5TRzbcU6oVK0W6K5QtUi9RY7tSByahN3sgX-PJ3GWbUHcojhxYo89843nBXAomSm5cIwyVpWUe_hGS5dwyqVJy1JKJTMMTp4v5Ow7_3IlrsKB2zq4VY48sWfUtjF4Rn7sBbeXvImK5cf2J8WqUWhdDSU07sIeZk4XE9j7dLb4drnlxdngdehxREw9lGEhQi9O1XFTYwbDRB5hltUdmXSbM--Iplu20l4EnT-ChwE7kpOB2I_hjquncG-oJvlrCvunY_G2KdyfB5v5E3CeBaDnubPk-scl9ZKdipbo2pIVpm0db3OladqS3nUda2A50jXEo0Oy3rTBWbYmTUUwKKRZ--3RXGuCx_7EIop8Csvzs-XpjIbiCtR4DaGjVaU9jXSlRGWTpFK5dalXZ6SzxiQ2tzrlopSVdTxFFU6j5sJKa2ySZ3j9DCZ1U7sXQFSVKKmFzrQ1nOtciRj7E6WwilXCRHA4zm7RDik0it70narCE6FAIhRSRfABZ77AjdWttNEhPsB_BFNUFSeY2c2rj4JFcHDjST-15mbzSLsibMh1gWoUSz3W_Xfzn9UVwbttM3aMPmi1azbYRerZYZ6xOILnw5LYjodlca8JR_B-XCM73_57sC___xNvYX-2nF8UF58XX1_BA3ypdyCUBzDpVhv32gOhrnwTVvtvdX8Ckg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVrRcECyvQAEjFXEymzix4z2hUroqj66qqki9RY4fEocm230c-PfMZJ1lWxC3KE7s2DOeR-bzDMCBErYupBdciFDzAs03Xvus4IWyeV0rpVVJh5NPp-rkR_H1Ul5G_NMiwip7mdgJatda-kc-QsWNmjfTqRqFCIs4-zz5OLvmVEGKIq2xnMZd2EGtmIoB7Hw6np6db-RyuUYgok2RcjRrRDytl-Z61DaUzTBTHyjj6pZ-ui2lt9TUrbhpp44mD-FBtCPZ4Zrwj-COb4Zwb11Z8tcQ9o76Qm5D2D2N8fPH4FEcEArdO3b185yjludyxkzj2JxSuPa3C214PmMdjJ3qYXm2bBlaimyxmkXgbMPawOiASLvArdJeGUYhAObIonwCF5Pji6MTHgstcIvewpKHYJBeJmgZXJYFPXY-R9dGeWdt5sbO5IWsVXC-yMmdM-TFiNpZl41Lun4Kg6Zt_HNgOmRaGWlK42xRmLGWKfUna-m0CNImcNCvbjVbp9OoujB4riskQkVEqJRO4D2tfEWbbDk31sSzAjgIpauqDinLG7qSUiSwf-NJXFp7s7mnXRU356Iil0rkaPf-u_kPpyXwdtNMHRMerfHtirrIUTSOS5Em8GzNEpv5iDLtvOIE3vU8sjX235N98f-PeAO7yOjV9y_Tby_hPr3TYQnVPgyW85V_hTbRsn4dmf03uM0Gvw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+miR-155-5p+and+reduced+miR-148a-3p+contribute+to+the+suppression+of+osteosarcoma+cell+death&rft.jtitle=Oncogene&rft.au=Bhattacharya%2C+S&rft.au=Chalk%2C+A+M&rft.au=Ng+A+J+M&rft.au=Martin%2C+T+J&rft.date=2016-10-06&rft.pub=Nature+Publishing+Group&rft.issn=0950-9232&rft.eissn=1476-5594&rft.volume=35&rft.issue=40&rft.spage=5282&rft.epage=5294&rft_id=info:doi/10.1038%2Fonc.2016.68&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9232&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9232&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9232&client=summon